Uncover key drivers, emerging technologies, and competitive movements shaping the neglected tropical disease treatment market from 2026–2035 with trusted insights from The Business Research Company
Starting from its 2026 valuation, what market size is the Neglected Tropical Disease Treatment Market expected to reach by 2030?
The neglected tropical disease treatment market size has experienced substantial expansion in recent years. It is forecast to grow from $3.57 billion in 2025 to $3.8 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. The historical increase can be ascribed to factors such as persistent disease prevalence in tropical regions, backing from global health organizations, the expansion of donor-funded treatment programs, the availability of generic therapeutics, and intensified public health awareness initiatives.
The neglected tropical disease treatment market size is projected to experience robust expansion over the coming years. It is set to grow to $4.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. During the forecast period, this expansion is primarily driven by greater investments in eradication initiatives, the growing adoption of integrated disease management strategies, the broader development of new antiparasitic drugs, an increase in public-private collaborations, and an enhanced emphasis on providing healthcare access in remote regions. Key trends anticipated for this timeframe involve the wider application of combination drug treatments, a heightened focus on early disease detection programs, the increased utilization of mass drug administration techniques, the growth of community-centered treatment frameworks, and an amplified focus on ensuring treatment accessibility.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24616&type=smp
What Drivers Are Driving Adoption Within The Neglected Tropical Disease Treatment Market?
The increasing occurrence of infectious ailments is anticipated to fuel the expansion of the neglected tropical disease treatment market in the coming years. Such diseases are health conditions resulting from detrimental microorganisms like bacteria, viruses, fungi, or parasites, which can be transmitted between individuals through direct or indirect contact. The uptick in these diseases stems from increased global travel, which accelerates the cross-border dissemination of pathogens. Treatment for neglected tropical diseases assists in combating infectious diseases by offering specific interventions to manage and eradicate their spread. These therapies enhance public health outcomes, particularly for susceptible populations, by alleviating disease impact and averting lasting impairments. For example, in February 2024, the UK Health Security Agency, a UK-based government body, reported that tuberculosis cases in England climbed to 4,850 in 2023, marking a 10.7% rise from 4,380 cases recorded in 2022. Consequently, the growing incidence of infectious diseases is propelling the growth of the neglected tropical disease treatment market.
What Segments Are Included Within The Neglected Tropical Disease Treatment Market?
The neglected tropical disease treatment market covered in this report is segmented –
1) By Drug Class: Anti-Parasite, Antifungal, Antibiotics, Other Drugs Class
2) By Disease Type: Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease, African Trypanosomiasis, Other Disease Types
3) By Route of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End User: Hospital, Specialty Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Anti-Parasite: Anthelmintics, Antiprotozoals, Antimalarials, Ectoparasiticides
2) By Antifungal: Azoles, Polyenes, Allylamines, Echinocandins
3) By Antibiotics: Tetracyclines, Macrolides, Rifamycins, Sulfonamides
4) By Other Drug Classes: Antivirals, Corticosteroids, Combination Therapies, Supportive Treatments
What Long-Term Trends Are Expected To Shape The Future Of The Neglected Tropical Disease Treatment Market?
Leading firms within the neglected tropical disease treatment market are concentrating on creating novel solutions, such as oral, field-ready therapies, aimed at streamlining delivery, enhancing patient safety, and broadening availability in regions with limited resources. Oral medications for conditions such as human African trypanosomiasis utilize small-molecule compounds administered orally over a brief duration, thereby boosting the reach of treatment, diminishing the necessity for hospital stays, and reducing operational difficulties when compared to conventional injectable treatments. For instance, in December 2023, Sanofi S.A., a multinational pharmaceutical company based in France, launched Fexinidazole Winthrop, an oral therapy developed through collaborations with non-profit organizations. Fexinidazole, a small molecule containing a nitro group, is designed to supersede earlier treatment protocols that mandated intravenous administration or hospitalization. Its oral formulation, simplified dosing regimen, and favorable safety profile render it appropriate for use across both phases of specific types of sleeping sickness, thereby extending treatment access to remote areas. Moreover, Fexinidazole stands in contrast to established alternatives like melarsoprol and eflornithine, which are administered via injection, demand intricate patient monitoring, and present greater toxicity or operational complexities.
Who Are The Prominent Global Companies Shaping The Neglected Tropical Disease Treatment Market Landscape?
Major companies operating in the neglected tropical disease treatment market are Pfizer Inc, Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Eisai Co Ltd, Shionogi And Co Ltd, Dr Reddys Laboratories Ltd, Cipla Ltd, Gilead Sciences Inc, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Lupin Limited, Alvogen
Access The Complete Report For Deeper Market Insights:
Which Region Is Projected To Lead The Neglected Tropical Disease Treatment Market During The Forecast Period?
Asia-Pacific was the largest region in the neglected tropical disease treatment market in 2025. The regions covered in the neglected tropical disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Neglected Tropical Disease Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24616&type=smp
Browse Through More Reports Similar to the Global Neglected Tropical Disease Treatment Market 2026, By The Business Research Company
Influenza Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report
Malaria Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/malaria-treatment-global-market-report
Infectious Disease Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









